Author

Yang Zheng

Institution: Fosun Pharma (China)

Observed institution: Fosun Pharma (China)

ORCID: 0009-0008-9300-0486

Observed ORCID: 0009-0008-9300-0486

OpenAlex ID: A5136035395

A Phase 2 Study of the MEK1/2 Inhibitor Luvometinib in Patients with Extracranial Arteriovenous Malformations

2026 · Chen Hua, Zhuli Wu, et al. · Clinical Cancer Research · 1

Supplementary Table S3 from A Phase 2 Study of the MEK1/2 Inhibitor Luvometinib in Patients with Extracranial Arteriovenous Malformations

2026 · Chen Hua, Zhuli Wu, et al.

Supplementary Table S6 from A Phase 2 Study of the MEK1/2 Inhibitor Luvometinib in Patients with Extracranial Arteriovenous Malformations

2026 · Chen Hua, Zhuli Wu, et al.

Supplementary Table S1 from A Phase 2 Study of the MEK1/2 Inhibitor Luvometinib in Patients with Extracranial Arteriovenous Malformations

2026 · Chen Hua, Zhuli Wu, et al.

Supplementary Figure S1 from A Phase 2 Study of the MEK1/2 Inhibitor Luvometinib in Patients with Extracranial Arteriovenous Malformations

2026 · Chen Hua, Zhuli Wu, et al.

Data from A Phase 2 Study of the MEK1/2 Inhibitor Luvometinib in Patients with Extracranial Arteriovenous Malformations

2026 · Chen Hua, Zhuli Wu, et al.

Supplementary Table S4 from A Phase 2 Study of the MEK1/2 Inhibitor Luvometinib in Patients with Extracranial Arteriovenous Malformations

2026 · Chen Hua, Zhuli Wu, et al.

Supplementary Figure S2 from A Phase 2 Study of the MEK1/2 Inhibitor Luvometinib in Patients with Extracranial Arteriovenous Malformations

2026 · Chen Hua, Zhuli Wu, et al.

Supplementary Table S2 from A Phase 2 Study of the MEK1/2 Inhibitor Luvometinib in Patients with Extracranial Arteriovenous Malformations

2026 · Chen Hua, Zhuli Wu, et al.

Supplementary Table S5 from A Phase 2 Study of the MEK1/2 Inhibitor Luvometinib in Patients with Extracranial Arteriovenous Malformations

2026 · Chen Hua, Zhuli Wu, et al.

Luvometinib in recurrent/refractory pediatric Langerhans cell histiocytosis: a single-arm, multi-center, phase 2 trial

2026 · Rui Zhang, Rong Liu, et al. · Blood Cancer Journal

Works count: 11

Citation count: 1

H-index: 1

I10-index: